Management of Elevated PT and INR

Patient Assessment and Management

• The American College of Cardiology recommends determining whether the patient is on warfarin or other vitamin K antagonists, as this fundamentally changes management and is the most common cause of elevated PT and INR values 1
• Checking platelet count immediately is crucial to rule out concurrent thrombocytopenia, which increases bleeding risk five-fold when combined with coagulopathy 1
• Reviewing medication history for antiplatelet agents, heparin, or direct oral anticoagulants is necessary, as these require different management strategies 1
• For patients with INR >1.7 or PT >15 seconds, thrombolysis is absolutely contraindicated, according to the American Heart Association 2, 3, 1
• The American Stroke Association recommends that INR must be ≤1.7 and PT ≤15 seconds for rtPA administration 2, 3, 1
• Current use of anticoagulant with INR >1.7 or PT >15 seconds is an absolute exclusion criterion for rtPA, as stated by the American College of Cardiology 2, 3
• Treatment with IV rtPA can be initiated before coagulation results are available in patients without recent anticoagulant use, but must be discontinued if INR >1.7 or PT elevated, according to the American Heart Association 2, 3
• Unexplained PT/INR elevation requires investigation for liver disease, vitamin K deficiency, factor deficiencies, or consumptive coagulopathy, as recommended by the American College of Cardiology 1
• Obtaining complete blood count, fibrinogen, D-dimer, liver function tests, and activated partial thromboplastin time (aPTT) is necessary for patients with unexplained PT/INR elevation, according to the American Society of Clinical Oncology 4
• PT/INR may be mildly elevated in COVID-19 without indicating warfarin effect, as noted by the American College of Cardiology 1
• In liver disease, PT/INR may be prolonged but does not reliably predict bleeding risk, according to the American Association for the Study of Liver Diseases 5

Reversal Strategies

• Prothrombin complex concentrate (PCC) is strongly preferred over fresh frozen plasma because onset of action is rapid, as recommended by the American College of Cardiology 1
• PCC dosing based on INR: for INR 2-3.9 give 25 units/kg, according to the American College of Cardiology 1
• Do not restart anticoagulation within 24 hours of major bleeding without repeat imaging and hematology consultation, as advised by the American College of Cardiology 1
• Do not rely on PT/INR for monitoring direct oral anticoagulants (DOACs); specialized tests are necessary, according to the American College of Cardiology 5

Monitoring Quality

• Maintaining INR monitoring quality by ensuring patients are in therapeutic range >56% of time through anticoagulation clinics or computer-assisted management is crucial, as recommended by the American College of Cardiology 1